Simultaneous administration of vardenafil and alcohol does not result in a pharmacodynamic or pharmacokinetic interaction in healthy male subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 5, 2006, Pages 216-224

  Wensing, Georg ^a   Bauer, R ^a   Unger, S ^a   Rohde, G ^a   Heinig, R ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Alcohol; Interaction; Pharmaco dynamic; Pharmacokinetic; Vardenafil

Indexed keywords

ALCOHOL; DRUG METABOLITE; PLACEBO; VARDENAFIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG ALCOHOL INTERACTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HEART RATE; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; NOSE CONGESTION; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SPHYGMOMANOMETRY; STATISTICAL SIGNIFICANCE; SUPINE POSITION; SYSTOLIC BLOOD PRESSURE; VASODILATATION;

EID: 33646413660     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44216     Document Type: Article

References (24)

1. Abe H, Kawano Y, Kojima S, Ashida T, Kuramochi M, Matsuoka H, Omae T, Biphasic effects of repeated alcohol intake on 24-hour blood pressure in hypertensive patients. Circulation. 1994; 89: 2626-2633.
2. Acevado CG, Carrasco G, Burotto M, Rojas S, Bravo I. Ethanol inhibits L-arginine uptake and enhances NO formation in human placenta. Life Sci. 2001; 68: 2893-2903.
3. Bischoff E. Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. Int J Impot Res. 2004; 16 (Suppl 1): S34-37.
4. Borne P van de, Mark AL, Montano N, Mion D, Somers VK. Effects of alcohol on sympathetic activity, hemodynamics, and chemoreflex sensitivity. Hypertension. 1997; 29: 1278-1283.
5. Boyce EG, Umland EM. Sildenafil citrate: a therapeutic update. Clin Ther. 2001; 23: 2-23.
6. Diebolt M, Bucher B, Andriantsitohaina R. Wine polyphenols decrease blood pressure, improve NO vasodilatation, and induce gene expression. Hypertension. 2001; 38: 159-165.
7. Frey R, Schmitz H. Blutdruck und Herzfrequenzverhalten von Probanden unter Normalbedingungen. In: Lange L, Jaeger H, Seifert W, Klingmann I (eds). Konzepte in der Humanpharmakologie. Pharmakodynamische Modelle für die Arzneimittelentwicklung. Heidelberg: Springer; 1993. p. 353-365.
8. Giuliano F, Donatucci C, Montorsi F, Auerbach S, Karlin G, Norenberg C, Homering M, Segerson T, Eardley I. Vardenafil is effective and well-tolerated for treating erectile dysfunction in a broad population of men, irrespective of age. BJU Int. 2005; 95: 110-116.
9. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixeddose study. Diabetes Care. 2003; 26: 777-783.
10. Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol. 2005; 45: 987-1003.
11. Halcox JP, Nour KR, Zalos G, Mincemoyer RA, Waclawiw M, Rivera CE et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol. 2002; 40: 1232-1240.
12. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl. 2002; 23: 763-771.
13. Keating GM, Scott LJ. Vardenafil: a review of its use in erectile dysfunction. Drugs. 2003; 63: 2673-2703.
14. Klotz T, Sachse R, Heidrich A, Jockenhovel F, Rohde G, Wensing G, Horstmann R, Engelmann R. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol. 2001; 19: 32-39.
15. Leslie SJ, Atkins G, Oliver JJ, Webb DJ. No adverse hemodynamic interaction between sildenafil and red wine. Clin Pharmacol Ther. 2004; 76: 365-370.
16. Lue TF. Erectile dysfunction. N Engl J Med. 2000; 342: 1802-1813.
17. Mitchell M, Sanderson B, Payne C, Bedding A. Pharmacodynamic interaction between alcohol and tadalafil in healthy volunteers. Int J Impot Res. 2002; 14 (Suppl 4): S64 P-112.
18. Ormrod D, Easthope SE, Figgitt DP. Vardenafil. Drugs Aging. 2002; 19: 217-227, discussion 228-229.
19. Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E, Bandel T. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first athome clinical trial. Int J Impot Res. 2001; 13: 192-199.
20. Saenz de Tejada I, Angulo J, Cuevas P, Fernandez A, Moncada I, Allona A, Lledo E, Korschen HG, Niewohner U, Haning H, Pages E, Bischoff E. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res. 2001; 13: 282-290.
21. Stark S, Sachse R, Liedl T, Hensen J, Rohde G, Wensing G, Horstmann R, Schrott KM. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol. 2001; 40: 181-190.
22. Venkov CD, Myers PR, Tanner MA, Su M, Vaughan DE. Ethanol increases endothelial nitric oxide production through modulation of nitric oxide synthase expression. Thromb Haemost. 1999; 81: 638-642.
23. www.fda.gov/cder/foi/label.2003/021400lbl.pdf. 2005.
24. Zusman RM, Morales A, Glasser DB, Osterloh IH. Over-all cardiovascular profile of sildenafil citrate. Am J Cardiol. 1999; 83: 35C-44C.